OFX

OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model. 


We're delighted to introduce our first episode in our video series, OFX Currency Corner. Our resident experts will provide insights on relevant events and trends that impact major currency markets. And what this could mean for you.

In episode one, we look back on the events of 2017 and resultant currency movements. We also take a view on upcoming factors you need to watch out for this month, to help you make the right transfer decisions for your business.

https://www.youtube.com/user/ozforex 

Company Type
Twitter Account
@OFX

Oncimmune

Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.

Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.

Company Type
Keywords
Twitter Account
@OncimmuneECDT

Oxstem

OxStem is a drug discovery company, spun-out from the University of Oxford in 2016, with the unique vision of developing small molecule therapeutics that augment repair mechanisms that already exist within the body. OxStem is developing drug candidates that can awaken endogenous cells to repair tissues affected by disease or injury to treat diseases such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world) and Oncology.

Company Type
Twitter Account
@OxStem

Pneumagen

Business development consultancy

Precision for Medicine, Oncology & Rare Disease

Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.

Contact Precision for Medicine, Oncology and Rare Disease via their website

Company Type
Twitter Account
@Precision4Med

Redx Pharma

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.

Company Type
Twitter Account
@RedxPharma

Sareum

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

Website:
www.sareum.co.uk
Company Type
Twitter Account
@Sareumplc

Sekisui Diagnostics

Sekisui Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years. We continue to invest in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners.

Company Type
Keywords
Twitter Account
@SekisuiDx

Selcia Ltd

Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling. In January 2018 Selcia became part of Eurofins Pharma Discovery Services affording Selcia the capacity to deliver extensive and seamless solutions and services that span the whole spectrum of drug discovery.

Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated.  USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.

Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.

Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.

Areas of Expertise:

• Medicinal chemistry:  Tool compounds; peptides; macrocycles; natural product chemistry

• Biology: Assay development; ADME screens;  PPIase profiling

• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology

• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions

• 14C Custom Radiosynthesis

• GMP 14C Radiolabelled API for Clinical Trials

• GLP/GMP Analytics – GLP NMR

• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds

contact@selcia.com

Company Type
Keywords
Twitter Account
@SelciaLtd

Silence Therapeutics

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.